Good
Mostly Aligned
Patient Risk:
Low
Summary
Most claims match the provided FDA label excerpts (indication, oral tablet, dosing concept, adverse reaction examples). However, several safety/monitoring claims are not directly supported by the provided excerpts (dose contingency wording, and the rationale for monitoring beyond tumor).
Category Scores
Accurate Statements
Tabrecta is a brand name for capmatinib.
Drug identification: TABRECTA (capmatinib) is the drug name and active ingredient.
Tabrecta (capmatinib) is an oral cancer medicine.
Dosage form: oral tablets (film-coated); Indication for NSCLC treatment.
Tabrecta is used to treat non-small cell lung cancer (NSCLC) with MET exon 14 skipping (METex14).
INDICATIONS AND USAGE: metastatic NSCLC with mutation leading to MET exon 14 skipping.
Tabrecta is taken as an oral tablet.
DOSAGE AND ADMINISTRATION: “400 mg orally twice daily”; Dosage form: oral tablets; “Swallow TABRECTA tablets whole.”
The exact dose and schedule of Tabrecta depend on the patient’s situation and how they tolerate the medicine.
DOSAGE MODIFICATIONS: dose reductions for management of adverse reactions; permanently discontinue if unable to tolerate 200 mg orally twice daily.
Dose changes for side effects may be required with Tabrecta.
DOSAGE MODIFICATIONS for Adverse Reactions: dose reductions listed in Table 1; permanent discontinuation for inability to tolerate 200 mg BID.
Common side effects reported with MET inhibitors like capmatinib include nausea and vomiting.
ADVERSE REACTIONS (6.1): most common adverse reactions include nausea and vomiting.
Common side effects reported with MET inhibitors like capmatinib include swelling (edema).
ADVERSE REACTIONS (6.1): most common adverse reactions include edema.
Common side effects reported with MET inhibitors like capmatinib include fatigue.
ADVERSE REACTIONS (6.1): most common adverse reactions include fatigue.
Common side effects reported with MET inhibitors like capmatinib include shortness of breath.
ADVERSE REACTIONS (6.1): most common adverse reactions include dyspnea.
Common side effects reported with MET inhibitors like capmatinib include liver enzyme elevations (abnormal liver blood tests).
WARNINGS AND PRECAUTIONS: Hepatotoxicity occurred; ADVERSE REACTIONS section notes hepatotoxicity (not explicitly “liver enzyme elevations” in provided excerpt, but hepatotoxicity supports liver-related lab effects being part of hepatotoxicity).
Unsupported Statements
Tabrecta is used in cases where the NSCLC has progressed after other treatment.
The provided label excerpts for INDICATIONS AND USAGE do not mention prior-treatment/progression requirement. No supporting language is present in the excerpted indication.
Clinicians typically monitor symptoms and lab values during treatment with MET inhibitors because they can affect organs beyond the tumor.
The provided excerpts mention specific risks (e.g., ILD/pneumonitis, hepatotoxicity, pancreatic toxicity) but do not provide monitoring recommendations or the stated rationale in the excerpt.
Contradictions
Important Omissions
Recommended dosage regimen details (400 mg orally twice daily with or without food) and tablet administration instructions (swallow whole; do not break/crush/chew), and missed/vomited dose instruction (do not make up; take next scheduled dose).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
No direct contraindications or safety instructions were given that conflict with the label. Some claims are unsupported (prior progression requirement; generalized monitoring rationale), but they do not introduce a clear direct contradiction to the provided excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Unsupported/additionally specified treatment context (prior progression after other therapy) and unsupported monitoring rationale.
Suggested Improvement
Limit indication wording to the label excerpt (adult metastatic NSCLC with MET exon 14 skipping as detected by an FDA-approved test) and avoid claiming label-based monitoring rationale unless explicitly supported in the provided prescribing information. Optionally add the label’s specific dosing and administration instructions (400 mg twice daily; swallow whole; missed/vomited dose guidance).